Literature DB >> 16225893

Accessibility to residues in transmembrane segment four of the glycine receptor.

Ingrid A Lobo1, James R Trudell, R Adron Harris.   

Abstract

Glycine receptors (GlyRs) are members of the ligand-gated ion channel superfamily. Each subunit has four transmembrane segments (TM1-TM4). Several studies suggest that amino acids in all four TMs face into a water-filled, alcohol and anesthetic binding cavity in the extracellular portion of the transmembrane domain. TM4 should contribute a "wall" to this cavity, but the residues involved are unknown. Here, we determined the ability of an alcohol analog, propyl methanethiosulfonate (propyl MTS), to covalently react with twelve GlyR TM4 positions (I401-I412) after mutating the original amino acids to cysteines. Reactivity of a cysteine with propyl MTS implies that the cysteine is exposed to water. W407C, I409C, Y410C, and K411C showed altered receptor function following reaction with propyl MTS in the presence or absence of glycine. The cysteine mutations alone eliminated the effects of ethanol for I409C, Y410C, and K411C, and reduced the effects of octanol for I409C and isoflurane for K411C. The ability of propyl MTS to reduce isoflurane and chloroform potentiation was examined in the reactive mutants. Potentiation by isoflurane was significantly reduced for I409C after reaction. These data demonstrate water-accessibility of specific TM4 positions in the GlyR and suggest involvement of these residues with alcohol and anesthetic action.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16225893     DOI: 10.1016/j.neuropharm.2005.08.017

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  22 in total

1.  Covalent modification of a volatile anesthetic regulatory site activates TASK-3 (KCNK9) tandem-pore potassium channels.

Authors:  Kevin E Conway; Joseph F Cotten
Journal:  Mol Pharmacol       Date:  2011-12-06       Impact factor: 4.436

2.  Nicotinic acetylcholine receptor transmembrane mutations convert ivermectin from a positive to a negative allosteric modulator.

Authors:  Toby Collins; Neil S Millar
Journal:  Mol Pharmacol       Date:  2010-05-12       Impact factor: 4.436

Review 3.  Modulating inhibitory ligand-gated ion channels.

Authors:  Michael Cascio
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

4.  Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.

Authors:  Gareth T Young; Ruud Zwart; Alison S Walker; Emanuele Sher; Neil S Millar
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-12       Impact factor: 11.205

5.  The relative orientation of the TM3 and TM4 domains varies between α1 and α3 glycine receptors.

Authors:  Lu Han; Sahil Talwar; Joseph W Lynch
Journal:  ACS Chem Neurosci       Date:  2012-11-28       Impact factor: 4.418

Review 6.  Alcohol-binding sites in distinct brain proteins: the quest for atomic level resolution.

Authors:  Rebecca J Howard; Paul A Slesinger; Daryl L Davies; Joydip Das; James R Trudell; R Adron Harris
Journal:  Alcohol Clin Exp Res       Date:  2011-06-15       Impact factor: 3.455

Review 7.  Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.

Authors:  Dustin K Williams; Jingyi Wang; Roger L Papke
Journal:  Biochem Pharmacol       Date:  2011-05-14       Impact factor: 5.858

Review 8.  Structure and Pharmacologic Modulation of Inhibitory Glycine Receptors.

Authors:  Carlos F Burgos; Gonzalo E Yévenes; Luis G Aguayo
Journal:  Mol Pharmacol       Date:  2016-07-11       Impact factor: 4.436

Review 9.  Ethanol effects on glycinergic transmission: From molecular pharmacology to behavior responses.

Authors:  Carlos F Burgos; Braulio Muñoz; Leonardo Guzman; Luis G Aguayo
Journal:  Pharmacol Res       Date:  2015-07-06       Impact factor: 7.658

10.  Single-channel analysis of ethanol enhancement of glycine receptor function.

Authors:  Brian T Welsh; Beth E Goldstein; S John Mihic
Journal:  J Pharmacol Exp Ther       Date:  2009-04-20       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.